Show Summary Details
Page of

Simian Immunodeficiency Virus and Opiates 

Simian Immunodeficiency Virus and Opiates
Chapter:
Simian Immunodeficiency Virus and Opiates
Author(s):

Shilpa Buch

, Shannon Callen

, Paul Cheney

, and Anil Kumar

DOI:
10.1093/med/9780195399349.003.0030
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 May 2019

Substantial data supports the notion that opioids negatively affect the immune system and potentiate HIV disease progression. In the central nervous system, morphine appears to exacerbate the neuropathogenesis of HIV through widespread disruption of astroglial and microglial function and potentiation of glial-derived cytokines and chemokines. Morphine exposure also reduces the threshold for neurotoxicity by potentiating the deleterious effects of marginally toxic inflammatory viral products. It is not surprising, therefore, that drug abusers are reported to have higher rates of both HIV encephalitis and HIV-associated neurological disorders compared to infected non-drug abusers. At the same time, and somewhat confusingly, there is evidence from epidemiological, clinical, and laboratory studies suggesting that opiates can actually have protective effects on the progression of HIV infections. One of the most promising models for clarifying this ambiguous situation is the non-human primate model, especially models using SIV infection of macaque monkeys. This chapter describes research on HIV and opiates in general, with a particular focus on work involving the macaque monkey.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.